Inhibition of rat corneal angiogenesis by a nuclease-resistant RNA aptamer specific for angiopoietin-2
暂无分享,去创建一个
Siqing Shan | Mark W Dewhirst | M. Dewhirst | B. Sullenger | Rebekah R White | S. Shan | C. Rusconi | Bruce A Sullenger | C. Kontos | Christopher P Rusconi | Geetha Shetty | Christopher D Kontos | R. White | G. Shetty
[1] P. Carmeliet,et al. Heterogeneous vascular dependence of tumor cell populations. , 2001, The American journal of pathology.
[2] Douglas Hanahan,et al. Signaling Vascular Morphogenesis and Maintenance , 1997, Science.
[3] Thomas N. Sato,et al. Increased vascularization in mice overexpressing angiopoietin-1. , 1998, Science.
[4] K. Alitalo,et al. Biological action of angiopoietin-2 in a fibrin matrix model of angiogenesis is associated with activation of Tie2. , 2001, Cardiovascular research.
[5] A. Varki,et al. DNA aptamers block L-selectin function in vivo. Inhibition of human lymphocyte trafficking in SCID mice. , 1996, The Journal of clinical investigation.
[6] Thomas N. Sato,et al. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. , 1997, Science.
[7] R. D'Amato,et al. Genetic heterogeneity of angiogenesis in mice , 2000, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[8] B. Hicke,et al. Escort aptamers: a delivery service for diagnosis and therapy. , 2000, The Journal of clinical investigation.
[9] William Lee,et al. Angiopoietin-1 and -2 Coiled Coil Domains Mediate Distinct Homo-oligomerization Patterns, but Fibrinogen-like Domains Mediate Ligand Activity* , 1999, The Journal of Biological Chemistry.
[10] T. Lohman,et al. A double-filter method for nitrocellulose-filter binding: application to protein-nucleic acid interactions. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[11] Thomas N. Sato,et al. Leakage-resistant blood vessels in mice transgenically overexpressing angiopoietin-1. , 1999, Science.
[12] M. Makuuchi,et al. Biologic significance of angiopoietin-2 expression in human hepatocellular carcinoma. , 1999, The Journal of clinical investigation.
[13] L. Ellis,et al. Differential expression of angiopoietin‐1 and angiopoietin‐2 in colon carcinoma , 2001, Cancer.
[14] F. Eckstein,et al. Kinetic characterization of ribonuclease-resistant 2'-modified hammerhead ribozymes. , 1991, Science.
[15] S. Ringquist,et al. Anti-L-selectin aptamers: binding characteristics, pharmacokinetic parameters, and activity against an intravascular target in vivo. , 2000, Antisense & nucleic acid drug development.
[16] Daniel B. Rifkin,et al. Fibroblast Growth Factor-2 (FGF-2) Induces Vascular Endothelial Growth Factor (VEGF) Expression in the Endothelial Cells of Forming Capillaries: An Autocrine Mechanism Contributing to Angiogenesis , 1998, The Journal of cell biology.
[17] K. Plate,et al. Cell type-specific expression of angiopoietin-1 and angiopoietin-2 suggests a role in glioblastoma angiogenesis. , 1998, The American journal of pathology.
[18] L. Ellis,et al. The effects of angiopoietin-1 and -2 on tumor growth and angiogenesis in human colon cancer. , 2001, Cancer research.
[19] S. McLeskey,et al. Expression and function of angiopoietin-1 in breast cancer , 2000, British Journal of Cancer.
[20] C. Heldin,et al. Intimal Hyperplasia Recurs After Removal of PDGF-AB and -BB Inhibition in the Rat Carotid Artery Injury Model , 2000, Arteriosclerosis, thrombosis, and vascular biology.
[21] A. DeAnda,et al. Pilot study of the efficacy of a thrombin inhibitor for use during cardiopulmonary bypass. , 1994, The Annals of thoracic surgery.
[22] Thomas N. Sato,et al. Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel formation , 1995, Nature.
[23] Lawrence A. Yannuzzi,et al. PRECLINICAL AND PHASE 1A CLINICAL EVALUATION OF AN ANTI-VEGF PEGYLATED APTAMER (EYE001) FOR THE TREATMENT OF EXUDATIVE AGE-RELATED MACULAR DEGENERATION , 2002, Retina.
[24] N. Janjić,et al. Identifying consensus patterns and secondary structure in SELEX sequence sets. , 1996, Methods in enzymology.
[25] Pamela F. Jones,et al. Requisite Role of Angiopoietin-1, a Ligand for the TIE2 Receptor, during Embryonic Angiogenesis , 1996, Cell.
[26] A. Karpeisky,et al. Chemical Modification of Hammerhead Ribozymes , 1995, The Journal of Biological Chemistry.
[27] J. Sabina,et al. Expanded sequence dependence of thermodynamic parameters improves prediction of RNA secondary structure. , 1999, Journal of molecular biology.
[28] T. Zhang,et al. Liposome-anchored vascular endothelial growth factor aptamers. , 1998, Bioconjugate chemistry.
[29] M. Dewhirst,et al. The novel tubulin-binding drug BTO-956 inhibits R3230AC mammary carcinoma growth and angiogenesis in Fischer 344 rats. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[30] S. Kitano,et al. Angiopoietin-2 is related to tumor angiogenesis in gastric carcinoma: possible in vivo regulation via induction of proteases. , 2001, Cancer research.
[31] P. Carmeliet,et al. Angiogenesis in cancer and other diseases , 2000, Nature.
[32] B. Sullenger,et al. Generation of species cross-reactive aptamers using "toggle" SELEX. , 2001, Molecular therapy : the journal of the American Society of Gene Therapy.
[33] N. Glazer,et al. Angiopoietin-1 protects the adult vasculature against plasma leakage , 2000, Nature Medicine.
[34] M. Dewhirst,et al. Antiangiogenic gene therapy targeting the endothelium-specific receptor tyrosine kinase Tie2. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[35] Pamela F. Jones,et al. Isolation of Angiopoietin-1, a Ligand for the TIE2 Receptor, by Secretion-Trap Expression Cloning , 1996, Cell.
[36] S. Gill,et al. Detection and plasma pharmacokinetics of an anti-vascular endothelial growth factor oligonucleotide-aptamer (NX1838) in rhesus monkeys. , 1999, Journal of chromatography. B, Biomedical sciences and applications.
[37] P. Rao,et al. Expression of Tie2/Tek in breast tumour vasculature provides a new marker for evaluation of tumour angiogenesis. , 1998, British Journal of Cancer.
[38] Sheela M. Waugh,et al. 2′-Fluoropyrimidine RNA-based Aptamers to the 165-Amino Acid Form of Vascular Endothelial Growth Factor (VEGF165) , 1998, The Journal of Biological Chemistry.
[39] M. Dewhirst,et al. Tie2 expression and phosphorylation in angiogenic and quiescent adult tissues. , 1997, Circulation research.
[40] J. Isner,et al. Tie2 receptor ligands, angiopoietin-1 and angiopoietin-2, modulate VEGF-induced postnatal neovascularization. , 1998, Circulation research.
[41] Ji-Hye Kim,et al. Angiopoietin-2 at high concentration can enhance endothelial cell survival through the phosphatidylinositol 3′-kinase/Akt signal transduction pathway , 2000, Oncogene.
[42] J. Chae,et al. Coadministration of Angiopoietin-1 and Vascular Endothelial Growth Factor Enhances Collateral Vascularization , 2000, Arteriosclerosis, thrombosis, and vascular biology.
[43] T. Fitzwater,et al. A SELEX primer. , 1996, Methods in enzymology.
[44] G. Garcı́a-Cardeña,et al. Direct actions of angiopoietin-1 on human endothelium: evidence for network stabilization, cell survival, and interaction with other angiogenic growth factors. , 1999, Laboratory investigation; a journal of technical methods and pathology.
[45] M. Dewhirst,et al. Inhibition of tumor angiogenesis using a soluble receptor establishes a role for Tie2 in pathologic vascular growth. , 1997, The Journal of clinical investigation.
[46] S. Dooley,et al. The Effects of Platelet-Derived Growth Factor Antagonism in Experimental Glomerulonephritis Are Independent of the Transforming Growth Factor–β System , 2002 .
[47] C. Bucana,et al. Spatial and temporal expression of angiogenic molecules during tumor growth and progression. , 1998, Oncology research.
[48] G. Yancopoulos,et al. In Situ Expression of Angiopoietins in Astrocytomas Identifies Angiopoietin-2 as an Early Marker of Tumor Angiogenesis , 1999, Experimental Neurology.
[49] D. Hanahan,et al. Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. , 1999, Science.
[50] G. Yancopoulos,et al. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. , 1999, Science.
[51] M. Gertsenstein,et al. Dominant-negative and targeted null mutations in the endothelial receptor tyrosine kinase, tek, reveal a critical role in vasculogenesis of the embryo. , 1994, Genes & development.
[52] N. Bouck,et al. Assay and purification of naturally occurring inhibitor of angiogenesis. , 1991, Methods in enzymology.
[53] G. Martiny-Baron,et al. Two independent mechanisms essential for tumor angiogenesis: inhibition of human melanoma xenograft growth by interfering with either the vascular endothelial growth factor receptor pathway or the Tie-2 pathway. , 1999, Cancer research.
[54] Richard A. Lang,et al. Angiopoietin-2 displays VEGF-dependent modulation of capillary structure and endothelial cell survival in vivo , 2002, Proceedings of the National Academy of Sciences of the United States of America.